• If you are wondering whether Novo Nordisk's current share price lines up with its fundamentals, this article walks through the key valuation angles that matter to you.
• The stock last closed at US$36.91, with recent returns of 0.4% over 7 days, a 4.3% decline over 30 days, a 29.5% decline year to date, and a 38.1% decline over the past year. This may signal changing views on its risk and reward profile.
• Recent news coverage has focused on Novo Nordisk's position in the pharmaceuticals and biotech space, as investors weigh its long term product pipeline against current market sentiment. Headlines have also highlighted broader sector moves, providing additional context to the share price performance you see today.
• Novo Nordisk currently has a valuation score of 5/6. Next up is a closer look at how different valuation methods assess the stock today, and how a more holistic framework at the end of this article can help you interpret those numbers with greater clarity.

Find out why Novo Nordisk's -38.1% return over the last year is lagging behind its peers.

Approach 1: Novo Nordisk Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects the cash a business may generate in the future and then discounts those amounts back to today to estimate what the entire company could be worth now.

For Novo Nordisk, the model uses a 2 Stage Free Cash Flow to Equity approach in DKK. The latest twelve month free cash flow is DKK 52.1b. Analyst and extrapolated projections suggest free cash flow of DKK 45.3b in 2026 and DKK 111.1b in 2030, with further estimates running out to 2035, all discounted back to today using Simply Wall St’s methodology.

Pulling these discounted cash flows together, the DCF model arrives at an estimated intrinsic value of US$106.85 per share. Compared with the recent share price of US$36.91, this implies the stock screens as 65.5% undervalued on this model alone.

This is a large gap. If you put weight on long term cash flow projections and the assumptions behind them, Novo Nordisk currently looks attractively priced on a DCF basis.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Novo Nordisk is undervalued by 65.5%. Track this in your watchlist or portfolio, or discover 61 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Novo Nordisk.

Approach 2: Novo Nordisk Price vs Earnings

For profitable companies like Novo Nordisk, the P/E ratio is a useful yardstick because it ties the share price directly to the earnings you are effectively paying for. Investors usually expect higher P/E ratios when a company has stronger earnings growth prospects or lower perceived risk, and lower P/E ratios when growth expectations or confidence are weaker.

Novo Nordisk currently trades on a P/E of 10.19x, compared with the Pharmaceuticals industry average of 16.55x and a peer group average of 17.80x. Simply Wall St also calculates a proprietary “Fair Ratio” for the stock of 25.79x. This reflects what the P/E might reasonably be given factors such as its earnings growth profile, industry, profit margins, market cap and risk characteristics.

This Fair Ratio aims to be more tailored than a simple comparison with peers or the wider industry, because it adjusts for company specific features rather than assuming all businesses deserve similar multiples. Set against this Fair Ratio, Novo Nordisk’s current P/E suggests the stock is pricing in a lower multiple than the model implies.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Novo Nordisk Narrative

Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach your own story about Novo Nordisk to the numbers by linking your view of its products, competition and risks to a forecast for revenue, earnings and margins, and then to a Fair Value that you can compare with today’s price to inform your decision. That Fair Value updates automatically when fresh news or earnings arrive. One investor might build a more optimistic Novo Nordisk Narrative with a Fair Value near US$95 per ADR, while another might take a more cautious stance with a Fair Value closer to US$65.50, reflecting how different perspectives on the same company translate into different numbers.

Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.